vs
BIOLIFE SOLUTIONS INC（BLFS）与TransMedics Group, Inc.（TMDX）财务数据对比。点击上方公司名可切换其他公司
TransMedics Group, Inc.的季度营收约是BIOLIFE SOLUTIONS INC的8.6倍（$160.8M vs $18.8M）。TransMedics Group, Inc.净利率更高（65.6% vs 58.9%，领先6.6%）。TransMedics Group, Inc.同比增速更快（32.2% vs 24.3%）。过去两年TransMedics Group, Inc.的营收复合增速更高（28.8% vs 1.0%）
BIOLIFE SOLUTIONS INC专注于开发生物保存产品及冷链管理解决方案，服务于细胞与基因治疗、生物制药及再生医学领域，产品涵盖低温保存培养基、自动化解冻系统、温度监测工具，为全球相关企业、科研机构及临床实验室提供支持。
TransMedics Group, Inc.是一家专注于器官移植领域的医疗科技企业，核心产品器官护理系统可在运输过程中维持捐献器官的活性，提升心、肺、肝、肾移植手术的成功率，服务覆盖北美、欧洲及亚太地区的移植中心与器官获取组织。
BLFS vs TMDX — 直观对比
营收规模更大
TMDX
是对方的8.6倍
$18.8M
营收增速更快
TMDX
高出7.8%
24.3%
净利率更高
TMDX
高出6.6%
58.9%
两年增速更快
TMDX
近两年复合增速
1.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.8M | $160.8M |
| 净利润 | $11.1M | $105.4M |
| 毛利率 | — | 58.1% |
| 营业利润率 | 7.2% | 13.2% |
| 净利率 | 58.9% | 65.6% |
| 营收同比 | 24.3% | 32.2% |
| 净利润同比 | -11.1% | 1436.9% |
| 每股收益（稀释后） | $0.23 | $2.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLFSTMDX
| Q4 25 | $18.8M | $160.8M | ||
| Q3 25 | $28.1M | $143.8M | ||
| Q2 25 | $25.4M | $157.4M | ||
| Q1 25 | $23.9M | $143.5M | ||
| Q4 24 | $15.1M | $121.6M | ||
| Q3 24 | $21.4M | $108.8M | ||
| Q2 24 | $19.7M | $114.3M | ||
| Q1 24 | $18.4M | $96.8M |
净利润BLFSTMDX
| Q4 25 | $11.1M | $105.4M | ||
| Q3 25 | $621.0K | $24.3M | ||
| Q2 25 | $-15.8M | $34.9M | ||
| Q1 25 | $-448.0K | $25.7M | ||
| Q4 24 | $12.5M | $6.9M | ||
| Q3 24 | $-1.7M | $4.2M | ||
| Q2 24 | $-20.7M | $12.2M | ||
| Q1 24 | $-10.2M | $12.2M |
毛利率BLFSTMDX
| Q4 25 | — | 58.1% | ||
| Q3 25 | — | 58.8% | ||
| Q2 25 | — | 61.4% | ||
| Q1 25 | — | 61.5% | ||
| Q4 24 | — | 59.2% | ||
| Q3 24 | — | 55.9% | ||
| Q2 24 | — | 60.6% | ||
| Q1 24 | — | 61.9% |
营业利润率BLFSTMDX
| Q4 25 | 7.2% | 13.2% | ||
| Q3 25 | -0.3% | 16.2% | ||
| Q2 25 | -65.5% | 23.2% | ||
| Q1 25 | -5.1% | 19.1% | ||
| Q4 24 | 3.6% | 7.1% | ||
| Q3 24 | -2.0% | 3.6% | ||
| Q2 24 | -6.6% | 10.9% | ||
| Q1 24 | -17.9% | 12.8% |
净利率BLFSTMDX
| Q4 25 | 58.9% | 65.6% | ||
| Q3 25 | 2.2% | 16.9% | ||
| Q2 25 | -62.3% | 22.2% | ||
| Q1 25 | -1.9% | 17.9% | ||
| Q4 24 | 82.5% | 5.6% | ||
| Q3 24 | -8.0% | 3.9% | ||
| Q2 24 | -105.1% | 10.7% | ||
| Q1 24 | -55.4% | 12.6% |
每股收益（稀释后）BLFSTMDX
| Q4 25 | $0.23 | $2.59 | ||
| Q3 25 | $0.01 | $0.66 | ||
| Q2 25 | $-0.33 | $0.92 | ||
| Q1 25 | $-0.01 | $0.70 | ||
| Q4 24 | $0.27 | $0.19 | ||
| Q3 24 | $-0.04 | $0.12 | ||
| Q2 24 | $-0.45 | $0.35 | ||
| Q1 24 | $-0.22 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.0M | — |
| 总债务越低越好 | $5.0M | — |
| 股东权益账面价值 | $371.9M | $473.1M |
| 总资产 | $405.9M | $1.1B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资BLFSTMDX
| Q4 25 | $33.0M | — | ||
| Q3 25 | $29.5M | — | ||
| Q2 25 | $31.9M | — | ||
| Q1 25 | $66.9M | — | ||
| Q4 24 | $91.5M | — | ||
| Q3 24 | $24.0M | $330.1M | ||
| Q2 24 | $22.0M | $362.8M | ||
| Q1 24 | $29.7M | $350.2M |
总债务BLFSTMDX
| Q4 25 | $5.0M | — | ||
| Q3 25 | $7.5M | — | ||
| Q2 25 | $10.1M | — | ||
| Q1 25 | $12.9M | — | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $20.1M | — | ||
| Q2 24 | $21.1M | — | ||
| Q1 24 | $24.3M | — |
股东权益BLFSTMDX
| Q4 25 | $371.9M | $473.1M | ||
| Q3 25 | $353.7M | $355.2M | ||
| Q2 25 | $347.2M | $318.1M | ||
| Q1 25 | $352.6M | $266.3M | ||
| Q4 24 | $348.9M | $228.6M | ||
| Q3 24 | $325.5M | $209.9M | ||
| Q2 24 | $321.4M | $189.9M | ||
| Q1 24 | $333.4M | $159.5M |
总资产BLFSTMDX
| Q4 25 | $405.9M | $1.1B | ||
| Q3 25 | $392.1M | $946.0M | ||
| Q2 25 | $387.2M | $890.5M | ||
| Q1 25 | $395.1M | $837.5M | ||
| Q4 24 | $399.5M | $804.1M | ||
| Q3 24 | $381.7M | $785.6M | ||
| Q2 24 | $375.0M | $758.6M | ||
| Q1 24 | $401.6M | $723.8M |
负债/权益比BLFSTMDX
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.9M | $34.5M |
| 自由现金流经营现金流 - 资本支出 | — | $19.0M |
| 自由现金流率自由现金流/营收 | — | 11.8% |
| 资本支出强度资本支出/营收 | — | 9.7% |
| 现金转化率经营现金流/净利润 | 0.44× | 0.33× |
| 过去12个月自由现金流最近4个季度 | — | $133.6M |
8季度趋势，按日历期对齐
经营现金流BLFSTMDX
| Q4 25 | $4.9M | $34.5M | ||
| Q3 25 | $6.1M | $69.6M | ||
| Q2 25 | $7.4M | $91.6M | ||
| Q1 25 | $1.7M | $-2.9M | ||
| Q4 24 | $1.6M | $19.7M | ||
| Q3 24 | $4.8M | $6.9M | ||
| Q2 24 | $6.5M | $25.7M | ||
| Q1 24 | $-4.5M | $-3.4M |
自由现金流BLFSTMDX
| Q4 25 | — | $19.0M | ||
| Q3 25 | — | $61.9M | ||
| Q2 25 | — | $82.5M | ||
| Q1 25 | — | $-29.9M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | — | $-41.3M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $-47.6M |
自由现金流率BLFSTMDX
| Q4 25 | — | 11.8% | ||
| Q3 25 | — | 43.1% | ||
| Q2 25 | — | 52.4% | ||
| Q1 25 | — | -20.8% | ||
| Q4 24 | — | 5.0% | ||
| Q3 24 | — | -38.0% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | -49.2% |
资本支出强度BLFSTMDX
| Q4 25 | — | 9.7% | ||
| Q3 25 | — | 5.3% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 44.3% | ||
| Q2 24 | — | 20.8% | ||
| Q1 24 | — | 45.6% |
现金转化率BLFSTMDX
| Q4 25 | 0.44× | 0.33× | ||
| Q3 25 | 9.83× | 2.86× | ||
| Q2 25 | — | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | 0.13× | 2.87× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | -0.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLFS
暂无分部数据
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
